Fred Hutch's Value in Cancer Care conference, held November 6, focused on patient and provider burnout; the growing data ...

GVHD can range from mild and temporary to life-threatening and chronic — but the deadly, debilitating cases are rare now. As ...

Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...

A new $5.2 million grant from the Washington Research Foundation will help develop a new clinical trials program between Fred ...

In this episode of the Oncology Insights Podcast, Dr. Petros Grivas welcomes Dr. Christina Rodriguez to discuss her journey ...

On Oct. 9, 2025, Fred Hutch Cancer Center employees with decades of service were honored at a luncheon celebrating their ...

Viral immunologist Paul Thomas, PhD, is working to turn the “incredible potential” of the immune system into real-life diagnostic and therapeutic applications that will improve vaccination strategies ...

Our research on cell-based therapies also includes cutting-edge immunotherapies that harness the patient’s own immune cells to fight disease, including genetic engineering of immune cells to attack ...

Today, Fred Hutch announced that in 2025 the Obliteride community raised $9.2 million for groundbreaking research. This amount brings Obliteride’s cumulative fundraising total to more than $67 million ...

Zinc’s immune-boosting properties are well-established, but we’re still untangling how it works. In a new study published in late March in the scientific journal Blood, Fred Hutchinson Cancer Research ...

Worried about health effects from the U.S.’s increasingly smoky summers? One day, not far in the future, you may be able to pop a few pills that will help your cells pinpoint and extract the worst of ...